I r r i t a b l e B o w e l S y n d ro m e Edson

Guzman
Firmado digitalmente por Edson Guzman
Nombre de reconocimiento (DN): cn=Edson Guzman, o, ou,
email=edson_guzman@hotmail.com, c=PE
Fecha: 2018.12.02 19:41:24 -05'00'

What Treatments Really Work

a b,
Nuha Alammar, MBBS , Ellen Stein, MD *

KEYWORDS
 Irritable bowel syndrome (IBS)  Rome criteria  Constipation  Diarrhea

KEY POINTS
 Rome IV classification divides IBS into subtypes based on the predominant stool pattern.
 Dietary interventions, such as FODMAP-reduced diets, can be successful short-term
treatments for patients with IBS.
 Mind-body techniques such as hypnotherapy can improve symptom management in IBS.
 Targeted symptomatic relief for the patient’s predominant symptoms provides relief. In
addition to effective older medications that are inexpensive and reliable, there are also
newer treatments for IBS-D such as eluxadoline, and IBS-C with linaclotide, lubiprostone,
plecanatide, which also can provide durable relief.

INTRODUCTION

Irritable bowel syndrome (IBS) is a disorder of the gastrointestinal tract character-

ized by chronic abdominal pain and altered bowel habits in the absence of demon-
strable organic disease.1,2 Although only 10% of patients with IBS seek medical
attention,3 it is one of the most common diseases treated. In the United States,
IBS accounts for 25% to 50% of all referrals to gastroenterologists4; however,
40% of individuals who meet diagnostic criteria for IBS do not receive a formal
diagnosis.5

EPIDEMIOLOGY

It is estimated that IBS affects approximately 5% to 15% of Western populations.6

Lovell and Ford7 conducted a meta-analysis of the literature that demonstrated that
IBS is seen predominantly in women, with onset in those younger than 50 years,
with a global prevalence of 11.2%.

Disclosure Statement: No disclosures for either author.

a
Department of Medicine, Division of Gastroenterology, King Khalid University Hospital, King
Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia; b Department of Medicine, Division
of Gastroenterology, Johns Hopkins University, 4940 Eastern Avenue, 3rd Floor, Baltimore, MD
21224, USA
* Corresponding author.
E-mail address: estein6@jhmi.edu

Med Clin N Am 103 (2019) 137–152

https://doi.org/10.1016/j.mcna.2018.08.006 medical.theclinics.com
0025-7125/19/ª 2018 Elsevier Inc. All rights reserved.
138 Alammar & Stein

CLINICAL PRESENTATION

IBS can present with a wide range of gastrointestinal symptoms. Although abdominal
pain is among the most common symptoms, patients with IBS may also experience
bloating, a sensation of incomplete evacuation, urgency, diarrhea, straining, and con-
stipation.8 Abdominal pain in IBS is usually crampy in nature with variable location and
intensity.9 The pain is related to bowel movements, with relief of pain after bowel
movements for some patients, and pain worsening while having a bowel movement
for others.10 Meals and emotional stress exacerbate abdominal pain for some
patients.11
Patients with IBS often report altered bowel movements, such as diarrhea, consti-
pation, alternating diarrhea and constipation, or predominantly normal bowel move-
ments with occasional diarrhea or constipation. The Bristol stool scale (Fig. 1) can
help patients to identify which type of stool is most frequently observed in their bowel
movements.
Patients with IBS and diarrhea-predominant symptoms describe frequent soft
stools with an appearance of soft blobs, fluffy pieces, or watery liquid stools (type
5–7 on the Bristol stool scale). Bowel movements occur throughout the day and are
often associated with meals. Approximately half of patients with IBS report mucus
discharge with stools.12 Patients with IBS and constipation report hard stools with
infrequent bowel movements (type 1–2 on the Bristol stool scale). These patients
also commonly complain of incomplete evacuation and tenesmus. Women with IBS
are more prone to have constipation.11

CLASSIFICATION OF IRRITABLE BOWEL SYNDROME

The Rome criteria were established by functional bowel disease experts to help better
manage patients with abdominal symptoms consistent with IBS. Using this classifica-
tion, IBS is classified according to the predominant stool pattern13:
1. IBS with predominant constipation (IBS-C); greater than 25% hard stools and less
than 25% loose stools
2. IBS with predominant diarrhea (IBS-D): greater than 25% loose stools and less than
25% hard stools
3. IBS with mixed bowel habits (IBS-M): greater than 25% loose stools and greater
than 25% hard stools
4. IBS unclassified (IBS-U): less than 25% loose stools and less than 25% hard stools

RED FLAG SYMPTOMS

IBS symptoms may be nonspecific, but during evaluation of symptoms, it is impor-

tant to ask about “red flag” symptoms. These are not considered symptoms of IBS
and always require further evaluation. The red flag symptoms include the
following14:
 Age older than 50
 Nocturnal symptoms, especially diarrhea
 Bloody stool
 Fever
 Weight loss
 Abnormal laboratory tests (including anemia, elevated inflammatory markers)
 Family history of inflammatory bowel disease or colon cancer
 Irritable Bowel Syndrome 139

Fig. 1. The Bristol stool scale provides a visual tool for patients to classify their stool consis-
tency ranging from firm balls (type 1) to thin liquid (type 7). (Distributed with the kind
permission of Dr K. W. Heaton; formerly reader in medicine at the University of Bristol. Re-
produced as a service to the medical profession by Norgine Ltd. ª2017 Norgine group of
companies.)

PATHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROME

IBS is no longer regarded as an idiopathic bowel dysfunction that originates exclu-

sively from psychological stress. The pathophysiology of IBS is complex and is due
to a combination of several factors. No single specific cause for this disorder has
been identified.15 There are multiple areas of ongoing research into the underlying
140 Alammar & Stein

etiology of IBS, which include research on alterations in gastrointestinal motility,

visceral hypersensitivity and neuro-enteric dysregulation, the role of inflammation,
bile acids, alterations in fecal flora, bacterial overgrowth, the microbiome, food sensi-
tivity, and genetic predisposition.
Alterations in Gastrointestinal Motility
Motility abnormalities of the gastrointestinal (GI) tract are seen in some but not all pa-
tients with IBS. Approximately 25% of patients with constipation-predominant IBS
have slow colonic transit and 15% to 45% of patients with diarrhea-predominant
IBS were noted to have acceleration of colonic transit.16,17
Visceral Hypersensitivity
It was first demonstrated in 1973 that patients with IBS experienced an increased pain
response to rectal balloon distension compared with healthy individuals.18 Another
study showed that rectal distension in patients with IBS increased cerebral cortical ac-
tivity more than in controls.19
Food Hypersensitivity
Although well-defined food allergies are not common in patients with IBS, exacerba-
tion of IBS symptoms has been observed with certain foods, particularly in patients
with diarrhea-predominant IBS. These are termed food sensitivities, and are not true
immunoglobulin (Ig)E-mediated food allergies.
IBS symptoms also may be increased with high-fat meals. One study examined the
effect of a fat-rich liquid meal of 600 kcal on visceral perception in subjects with IBS
and healthy controls. The study demonstrated that postprandial, but not fasting, pain
scores were significantly elevated in patients with IBS.20 In another study examining
the correlation between meals and IBS, rectal sensitivity increased significantly in pa-
tients with IBS at 30 and 60 minutes after a high-fat meal.21 These studies suggest a
role for dietary fat content in IBS-related discomfort and pain.
Fecal Short-Chain Fatty Acids
Fecal short-chain fatty acids (SCFAs) may also play a role in IBS symptoms, as they
are increased in stool from patients with diarrhea-predominant IBS.22 SCFAs stimulate
colonic transit and motility through intraluminal release of 5-hydroxytryptamine
(5-HT)23 in rats. SCFAs also initiate high-amplitude propagated contractions in the co-
lon, propelling colonic content rapidly.24 Fermentable oligosaccharides, disaccha-
rides, monosaccharides, and polyols (FODMAPs), which are found in a variety of
foods, are poorly absorbed in the small intestine and may induce symptoms of
IBS25 through the production of SCFAs and their effects on colonic motility, contrac-
tions, and secretion.
Gluten
The role of gluten in IBS has been of interest to gastroenterology researchers and the
public. A randomized, placebo-controlled trial involving patients who previously re-
ported intolerance to gluten and a response to its withdrawal confirmed that gluten
was associated with symptoms of IBS.26 In a recent randomized controlled trial
(RCT) of a gluten-containing diet versus a gluten-free diet in patients with IBS-D, par-
ticipants ingesting gluten had increased stool frequency, increased bowel perme-
ability, and reduced messenger RNA expression of tight-junction proteins in the
bowel mucosa.27 In another study of patients with IBS with diarrhea, but without celiac
disease, researchers found that dietary gluten altered small intestinal permeability and
 Irritable Bowel Syndrome 141

had a greater effect on bowel movement frequency in patients who were HLA-DQ2/8
positive compared with those who were HLA-DQ2/8 negative.28
Fructose
Fructose intake can also contribute to symptoms of IBS. Fructose is a 6-carbon mono-
saccharide. It is naturally present in a variety of foods, such as fruits, vegetables, and
honey. It is also enzymatically produced from corn as high-fructose corn syrup, which
is a common food sweetener found in soft drinks and condiments. Approximately one-
third of patients with suspected IBS have fructose malabsorption and dietary fructose
intolerance.9 Malabsorption of fructose leads to water influx into the lumen due to os-
motic pressure. This, in turn, results in rapid propulsion of bowel contents into the co-
lon. Unabsorbed fructose is fermented by colonic bacteria, which results in the
production of SCFAs, hydrogen, carbon dioxide, and trace gases. This can result in
symptoms including abdominal pain, excessive gas, and bloating.29
Bile Acids
A systematic review of the literature suggested that bile acid malabsorption accounts
for approximately 30% of cases of IBS-D.30 In another study, approximately 25% of
patients with IBS-D had an elevated 48-hour total fecal bile acid excretion compared
with IBS-C. In this study, 40% of patients with IBS-D showed elevated bile acid syn-
thesis (as measured by the fasting concentration of a bile acid precursor) compared
with healthy controls and patients with IBS-C.31
Microbiota
The precise role of the fecal or mucosal microbiome in IBS is unclear. Studies of the
mucosa-associated microbiota in patients with IBS-D have shown increases in Bac-
teroides and Clostridia and a reduction in bifidobacteria.32 A negative relationship be-
tween the fecal abundance of bifidobacteria and pain score in IBS has been
reported.32,33 The role of the microbiome in IBS symptoms is suggested by meta-
analysis data showing the efficacy of probiotics,34 particularly for abdominal pain
and bloating. In addition, a probiotic mixture has been shown to slow colonic transit
in patients with IBS-D, suggesting that the gut microbiome may have a role in the
symptoms of IBS.35
Small Intestinal Bacterial Overgrowth
Small intestinal bacterial overgrowth (SIBO) also has been investigated as a contrib-
utor to IBS. Several studies have shown that some patients with IBS, especially pa-
tients with IBS-D, have an abnormal lactulose breath test (elevated breath
hydrogen), suggestive of SIBO. These same patients showed improvement in pain
and diarrhea after eradication of bacterial overgrowth.36,37 In addition to elevated
breath hydrogen, increased methane production during lactulose breath testing has
been seen in some patients with IBS-C.38
Inflammation
Mucosal inflammation has been associated with increased intestinal permeability and
may play a role in IBS. In some patients with IBS, there are increased levels of T lym-
phocytes, and in some cases, mast cells in the rectal mucosa.39 These data, in addi-
tion to the epidemiologic and clinical observations seen in patients with postinfectious
IBS,40 support a role of immune activation and altered bowel barrier function in a sub-
group of patients with IBS. Genetic susceptibility may confer a predisposition to im-
mune activation in a subset of patients with IBS.
142 Alammar & Stein

Genetic
Genetic factors may play a role in development of IBS. Some areas of research include
genetic differences in predisposition to inflammation, bile acid synthesis, and intesti-
nal secretion.

DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

Diagnosis of IBS is made based on clinical symptoms that meet the diagnostic criteria
and a basic evaluation to exclude other organic diseases that mimic the symptoms of
IBS. Due to the absence of specific blood test, markers, and imaging studies that can
help diagnose IBS, multiple definitions and diagnostic criteria have been used to diag-
nose IBS. The Rome consensus criteria were established in 1989 to help guide clini-
cians in understanding IBS. The most recent criteria, the Rome IV criteria, were
released in May of 2016.13

ROME IV

IBS is defined as recurrent abdominal pain for at least 1 day per week in the past
3 months, associated with 2 or more of the following criteria13:
 Related to defecation
 Associated with a change in stool frequency
 Associated with a change in stool form

CLINICAL EVALUATION
History and Physical Examination
This is the most important part of the evaluation because the diagnosis of IBS is pre-
dominantly based on symptoms. A complete history and physical can identify alarm
symptoms, and help to exclude conditions that might mimic the symptoms of IBS,
such as inflammatory bowel disease, celiac disease, or malignancy. Specific features
of the medical history that may be helpful include family history, medications, prior
history of viral or bacterial gastrointestinal infection, and symptoms related to fatty
meals or gluten. A thorough physical examination in the average patient with IBS
would typically be unrevealing. Findings such as dermatitis, rebound, guarding, point
tenderness, or blood in stool, joint dysfunction, or arthritis should prompt an appro-
priate workup for other causes of GI symptoms. Any patient presenting with red
flag/alarm symptoms should undergo further evaluation.
Laboratory Tests
A complete blood count helps to exclude anemia. Anemia, including iron deficiency
anemia, is not expected with IBS and requires further workup to identify the underlying
disorder. For patients with IBS-D, stool testing can be considered. Ova and parasite
testing, particularly if there is prior exposure to lake or spring water, can be performed
to look for infection. Inflammatory markers such as C-reactive protein or fecal lactofer-
rin can assess for inflammatory bowel disease. Celiac serologies (tissue transglutami-
nase IgA) can be checked to exclude celiac disease from the differential.

DIFFERENTIAL DIAGNOSIS

The differential diagnosis of IBS is broad. A good history and physical with a few lab-
oratory tests can help exclude celiac disease, inflammatory bowel disease, micro-
scopic colitis, post-cholecystectomy bile acid diarrhea, and SIBO. Patients with
 Irritable Bowel Syndrome 143

IBS-C also can have pelvic floor dysfunction or colonic transit disorders. If treatment
fails to improve symptoms, then additional evaluation may be required. A rectal exam-
ination can help to identify patients who also have dyssynergia or pelvic floor
problems.

MANAGEMENT

Management of IBS can include dietary modification, medications, and mind-body

treatments.

Dietary Intervention
Diet modification is one of the most commonly used interventions for patients
with IBS.41 A careful dietary history might suggest symptoms related to specific
foods.

Commonly Recommended Dietary Modifications

Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and
polyols
The low-FODMAP diet has been studied in patients with IBS. The acronym FODMAP
describes the oligosaccharides fructans and galacto-oligosaccharides present in
wheat, rye, onions, garlic, and legumes; the disaccharide lactose present in milk
and yogurt; the monosaccharide fructose (when consumed in excess of glucose) pre-
sent in honey, apples, pears, and high-fructose corn syrup; and polyols including sor-
bitol and mannitol present in apples, pears, stone fruit, and many artificially sweetened
gums and confectionary.42 The efficacy of the elimination phase of the low-FODMAP
diet for overall GI symptom relief in adult patients with IBS has been examined in
RCTs; a blinded, randomized, rechallenge study; and observational studies. These
studies have shown that 50% to 86% of patients have a clinically meaningful response
to the low-FODMAP diet.43
Fructans and galacto-oligosaccharides have prebiotic actions in the gastrointes-
tinal tract. Their restriction, in the setting of the low-FODMAP diet, may lead to a
reduction in beneficial bacteria. For this reason, it is generally recommended to
administer the low-FODMAP diet in 2 phases. The first phase is to assess the pa-
tient’s degree of benefit from the diet. This is best achieved through an initial phase
of strict elimination of foods high in FODMAPs, generally of 6 to 8 weeks’ duration,
guided by a specialist dietician. After finishing the initial 6 to 8 weeks of the low-
FODMAP diet, a follow-up consultation with a dietician is indicated. The patient’s
diet is then liberalized in a stepwise fashion to determine the type and amount of
FODMAPs that can be tolerated. This second phase tailors the low-FODMAP diet
to each patient to ensure that unnecessary dietary restriction is minimized and
maximum variety in the diet is achieved, while still maintaining a satisfactory level
of symptom control.42
High-fiber diet
Fiber supplementation has traditionally been recommended for patients with IBS and
has received much attention; however, most research studies examining the role of
fiber in treatment of IBS have shown no clear difference over placebo.44
Gas-producing foods
For patients with IBS, some benefit may occur from reducing gas-producing foods.
These include beans, onions, celery, carrots, raisins, bananas, apricots, prunes, Brus-
sels sprouts, wheat germ, pretzels, and bagels. Reduction in consumption of these
144 Alammar & Stein

foods may reduce gas formation, bloating, and flatulence. This diet is less restrictive
than the FODMAP diet.
Dietary Recommendations for Selected Cases
Gluten-free diet
Evidence to support gluten avoidance in patients with nonceliac gluten sensitivity
(NCGS) has been conflicting. In a randomized double-blind crossover trial, 59 patients
with NCGS on a gluten-free diet were assigned to receive gluten (without fructan),
fructan (without gluten), or placebo for 7 days.45 GI symptom rating scores and bloat-
ing were higher with fructan than with gluten. There was no difference in symptom
scores between gluten and placebo groups. This study suggests that symptomatic
improvement with a gluten-free diet in such patients may not be due to removal of
the gluten protein, but due to reduced exposure to fructan, which foods with gluten
often contain.
A role for the low-FODMAP diet in people with NCGS was recently suggested in a
double-blinded placebo-controlled crossover trial in patients with self-reported
NCGS.46 This study showed that gluten did not induce any specific GI symptoms in
the 37 participants; however, the provision of a low-FODMAP diet reduced symptoms
in all 37 participants, leading to greater symptom improvement than following a gluten-
free diet (P<.001).
Lactose-free diet
There is no evidence to suggest that the incidence of lactose malabsorption is higher
in patients with IBS. Some studies have shown that patients with IBS and lactose intol-
erance have an exaggerated symptom response to lactose ingestion.47 If a dietary his-
tory suggests lactose malabsorption, substantial relief of symptoms can be achieved
with lactase enzyme supplementation during mealtimes.
Less Frequently Used Diets in Clinical Practice
Elimination diet
More intensive elimination diets have been described, and in one small study of 25 pa-
tients, improvement of IBS symptoms was seen. The strict elimination diet consisted
of distilled or spring water, 1 meat, and 1 fruit for a week. Two-thirds of patients who
completed this diet noted symptom improvement followed by a worsening of symp-
toms when suspect foods were reintroduced.48,49 Extreme diets are not ideal for
long-term use and may cause nutritional deficiencies. It is not recommended to follow
overly restrictive diets to manage IBS symptoms.
Immunoglobulin G–related food symptoms
One study examined the potential role of IgG-related food responses as a guide for
symptom management. Patients with IBS in this 12-week randomized, blinded trial
received a diet excluding foods to which they had increased IgG antibodies. With
these dietary changes, the study patients showed improvement in IBS symptoms.48
At this time, there is insufficient evidence to support routine food allergy testing in pa-
tients with IBS. No GI society endorses IgG testing to guide food elimination diets for
IBS outside of a research setting. It is reasonable to avoid allergens in susceptible pa-
tients, provided this would not substantially impair their dietary intake.
Pharmacotherapy Targeted to Irritable Bowel Syndrome Symptoms
In addition to dietary modification, medications are helpful in managing IBS symp-
toms. Choice of medication will depend on the symptoms reported by the patient
(Table 1).
 Irritable Bowel Syndrome 145

Abdominal pain
Tricyclic antidepressants For the treatment of abdominal pain in IBS, antidepressants
have shown benefit in clinical studies and ideally should be started at low doses. The
initial dose should be adjusted based on tolerance and response. Tricyclic antidepres-
sants (TCAs) can slow the GI transit time due to their anticholinergic effect, which may
be particularly helpful in IBS-D. A systematic review showed a modest improvement in
global relief and abdominal pain in patients treated with TCAs, although the overall
body of evidence was of low quality. TCAs are a low-cost option for treatment of
symptoms in patients with IBS; however, they should be used with caution in patients
at risk for prolongation of the QT interval.50

Antispasmodics The antispasmodics hyoscyamine, dicyclomine, and peppermint

oil have also been studied in IBS. A meta-analysis showed significant improvement
in IBS-related global symptoms with antispasmodics. Studies also showed
modest improvement in abdominal pain symptoms with minimal risk of adverse ef-
fects.50 In another meta-analysis of 9 randomized placebo-controlled trials
including 726 patients, peppermint oil was found to be significantly superior to pla-
cebo for global improvement of IBS symptoms and improvement in abdominal
pain.51

Selective serotonin reuptake inhibitors

Selective serotonin reuptake inhibitors (SSRIs) have been extensively studied in IBS,
and results have been lackluster compared with TCAs. Pooled estimates from 5
RCTs show no improvement in global relief of symptoms. In addition, 4 RCTs showed
no improvement in abdominal pain. However, the risk of important adverse effects is
minimal. The American Gastroenterological Association recommends against using
SSRIs as primary therapy for patients with IBS, but as some studies did show a
benefit, they can still be considered as an option for treatment. Patients with depres-
sion do not need to discontinue SSRI therapy to improve IBS symptoms.50

Diarrhea
Rifaximin Rifaximin is an oral nonsystemic GI-targeted antibiotic that has in vitro ac-
tivity against a variety of gram-negative and gram-positive bacteria.52 Pooled data
from several studies of rifaximin in IBS showed a small, but beneficial, effect of rifax-
imin with improvement in abdominal pain and stool consistency. Three RCTs demon-
strated an improvement in IBS-related global symptoms. Additionally, these studies
showed small improvements in abdominal pain and bloating. Symptom relief was re-
ported, but few studies have documented sustained relief for all patients with IBS.50 It
is important to note that although side effects were minimal, the cost of treatment may
be quite high.

Loperamide Loperamide is a peripherally acting m-opioid receptor agonist. This is the

only antidiarrheal agent evaluated in randomized trials in patients with IBS-D. Data
investigating the use of loperamide specifically for the treatment of patients with
IBS-D, as opposed to symptomatic relief of diarrhea for other disease states, is very
limited. Two older RCTs that in the aggregate enrolled 42 patients failed to show a sig-
nificant benefit in global relief of IBS-related symptoms. However, the quality of evi-
dence from these trials was very low due to methodological concerns. There is a
large body of indirect evidence from a variety of other settings that shows the efficacy
of loperamide in reducing stool frequency. Therefore, because of low cost, wide avail-
ability, and minimal adverse effects, loperamide can be viewed as a useful adjunct to
other IBS-D therapies.50
146 Alammar & Stein

Bile acid sequestrants Bile acid sequestrants, such as cholestyramine, colestipol, and
colesevelam, can be used to manage IBS-D. Bile acid agents bind to luminal bile
acids, impeding reabsorption, and reducing stimulation of colonic transit. These
agents may be effective in patients with IBS-D, as bile acid diarrhea is due to either
increased bile acid synthesis or impaired reabsorption.53 In an open-label trial, cole-
sevelam showed evidence of intraluminal binding of bile acids and improved stool
consistency in patients with IBS-D.54 Bile acid sequestrants can be associated with
GI side effects, including bloating, flatulence, abdominal discomfort, and constipation.
Alosetron Alosetron is a 5-hydroxytryptamine-3 receptor antagonist. Based on
pooled data from multiple RCTs, patients treated with alosetron had improvement in
abdominal pain and IBS-related global symptoms. However, postmarketing data
from an observational study suggested that idiopathic, non–dose-dependent
ischemic colitis could occur with use (approximately 1 case/1000 patient-years).
The drug was voluntarily withdrawn from the market and subsequently reintroduced
only under a physician-based risk management program.50 Alosetron is used only
for the treatment of severe diarrhea-predominant IBS lasting for at least 6 months in
women who failed to respond to other treatments. Good candidates for this medica-
tion should have few risk factors for ischemic disease.

Eluxadoline Eluxadoline is a mu-opioid receptor agonist and a delta-opioid receptor

antagonist. Eluxadoline has been approved for treatment of IBS-D and can dramati-
cally reduce bowel movement frequency and improve consistency. It is contraindi-
cated in patients with history of biliary disease, severe liver disease (Child-Pugh
Class C), pancreatitis, and heavy alcohol use. It is also contraindicated in patients
without a gallbladder due to an increased incidence of severe acute pancreatitis noted
in postmarketing surveillance.55

Constipation
Laxatives are effective in increasing the frequency of bowel movements, and therefore
a simple way to manage the constipation symptom of IBS-C.

Polyethylene glycol laxatives A polyethylene glycol (PEG) laxative is an inexpensive

laxative that is easily tolerated by patients. It is mainly used in IBS-C to improve con-
stipation. There are several trials examining the use of PEG laxatives in patients with
chronic constipation; however, there is only one RCT evaluating the use of PEG solu-
tion for treating patients with IBS-C. This 4-week trial did not show a measurable effect
of PEG laxatives on IBS-related global symptom scores.50

Linaclotide Linaclotide is a guanylate cyclase C receptor agonist that increases

luminal chloride and fluid secretion through the generation of cyclic guanosine mono-
phosphate. Linaclotide is used for the treatment of IBS-C at a dosage of 290 mg daily.
Two randomized trials of linaclotide in patients with IBS-C showed a modest beneficial
effect with a combined improvement in abdominal pain and an increase in the number
of complete spontaneous bowel movements and improvement in global symptoms.
Diarrhea leading to treatment discontinuation occurred in a small percentage of
treated patients.50

Lubiprostone Lubiprostone is a chloride channel activator that triggers intestinal chlo-

ride secretion and sodium and fluid transit into the lumen. It is used for the treatment of
IBS-C at a dosage of 8 mg twice daily. Dosages can be escalated to 16 and 24 mg twice
daily in patients who do not respond completely to lower dosages. Two randomized
trials of lubiprostone were performed in patients with IBS-C. Most patients were
 Irritable Bowel Syndrome 147

women, and the placebo response in the studies was far lower than expected.56 In
these 2 multicenter, placebo-controlled trials, 1154 adults with IBS and constipation
were randomly assigned to lubiprostone (8 mg twice daily) or placebo for 12 weeks.
Patients randomized to lubiprostone were significantly more likely to achieve an over-
all symptom response (18% vs 10%). Serious adverse events were similar to placebo.
The most common adverse event was nausea (8% vs 4%). A follow-up open-label
study that included 522 patients demonstrated that benefits of lubiprostone persisted
or increased at 52 weeks. There are 2 RCTs of 12 weeks’ duration examining the effec-
tiveness of lubiprostone for global symptom relief in patients with IBS-C, with a pooled
effect estimate showing a small improvement in global symptoms of IBS. There were
few adverse effects from using lubiprostone.50

Plecanatide Plecanatide is a novel agent affecting guanylate cyclase recently

approved by the Food and Drug Administration for management of IBS-C. This medi-
cation promotes bowel transit and adds water to soften the stool as it passes through
the gut. A recent study demonstrated the efficacy and safety of plecanatide for both
pain and constipation symptoms.57
Mind-body techniques
Hypnotherapy Gut-directed hypnotherapy for IBS has been tested in RCTs, which have
shown efficacy in IBS cohorts.58 A recent randomized clinical trial compared the short-
term and long-term efficacy of gut-directed hypnotherapy and the low-FODMAP diet
and found similar durable effects for the relief of GI symptoms.59 Seventy-four patients
were randomly allocated to receive treatment via hypnotherapy (n 5 25), diet (n 5 24),
or both (n 5 25). Clinically significant improvements in overall GI symptoms were
observed from baseline to week 6 in 72%, 71%, and 73% of patients, respectively.
This improvement persisted 6 months posttreatment in 74%, 82%, and 54% of patients,
leading the researchers to conclude that gut-directed hypnotherapy showed efficacy
similar to the low-FODMAP diet, but no additional benefit when these modalities were
combined. Although IBS quality of life was significantly improved across all groups, hyp-
notherapy resulted in superior improvements in psychological indices.

Acupuncture Several studies have confirmed that acupuncture is effective treatment

for IBS, as it can regulate the brain-gut axis and improve visceral hyperactivity.60
Electro-acupuncture showed good therapeutic effect on C-IBS abdominal pain and
bloating. It also improved defecation frequency, constipation, difficulty in defecation,
and other main GI symptoms. Electro-acupuncture also alleviated depression, anxi-
ety, and other psychological symptoms, and also affected brain-related functional
areas.61
Cognitive behavioral therapy Cognitive behavioral therapy (CBT) has also been stud-
ied in patients with IBS. In an RCT, it was found that a home-based version of CBT
produced significant and long-term GI symptom improvement for patients with IBS
compared with IBS education alone.62

OVERALL STRATEGY FOR IRRITABLE BOWEL SYNDROME MANAGEMENT

The main strategy for management of symptoms in IBS is to improve each symptom,
starting with the symptom that is most bothersome to the patient. It is critical to form a
therapeutic alliance with the patient, building trust and confidence in a collaborative
approach. A therapeutic relationship begins with good communication, including car-
ing language in the visit, eye contact, and providing verbal reassurance that you as a
diagnostician will continue to work with the patient over time until the symptoms
148 Alammar & Stein

improve. For mild IBS symptoms, less intensive strategies, such as healthy diet (avoid-
ing junk food), improved quality of sleep, and relaxation strategies to avoid anxiety and
stress may be sufficient. A short dietary intervention with low-FODMAP foods can be
followed by an organized reintroduction of foods, to quantify the effect of trigger foods
on symptoms. A nutritionist can be very helpful and there are many online dietary re-
sources to help guide patients as well. A rational approach to long-term dietary change
is important. For moderate IBS with persistent symptoms, gut-directed medications
also can be helpful. For diarrhea-predominant symptoms, loperamide, rifaximin, or
bile acid binding agents can be trialed. For pain-predominant symptoms, tricyclic an-
tidepressants or SSRIs can be used. For constipation-predominant symptoms, chlo-
ride channel and guanylate cyclase agents can be considered, such as lubiprostone,
linaclotide, and plecanatide. For more severe daily symptoms that are troublesome
and persistent, some patients may require combination therapy, including dietary
modification, medications, and psychological interventions, such as CBT to help
manage symptoms. The combination of different types of therapy and a strong thera-
peutic alliance with the patient is a winning strategy for IBS symptom control.

Table 1
Medication strategies for symptom management in irritable bowel syndrome

Symptom Medication Strategy

Diarrhea-focused Loperamide 2 mg every few hours as needed, no more than 8 doses per
symptoms day
Cholestyramine 9 g twice or thrice daily
Colestipol 2 g daily or twice daily
Colesevelam 625 mg daily or twice daily as tolerated
Probiotics multiple formulations
Rifaximin 550 mg by mouth thrice daily for 14 d
Alosetron 0.5 mg to 1 mg daily as tolerated
Ondansetron 4–8 mg 3 times daily
Eluxadoline 100 mg twice daily as tolerated
Constipation-focused Psyllium 30 g daily in divided doses
symptoms Polyethylene glycol agents 17 g daily or twice daily
Lubiprostone 8 mg twice daily, titrate to 24 mg twice daily as tolerated
Linaclotide 290 mg daily, although 145-mg and 72-mg dosing also
available if not tolerated
Plecanatide 3 mg daily
Abdominal Dicyclomine 10 mg daily to 4 times daily, titrate up to 20 mg if needed
pain–focused Peppermint oil 250–750 mg twice daily or thrice daily
symptoms Desipramine 25–100 mg nightly
Amitriptyline 10–50 mg nightly
Paroxetine 10–40 mg daily
Sertraline 25–100 mg daily
Citalopram 10–40 mg daily
Linaclotide, alosetron, lubiprostone, and plecanatide show
improvement in pain relief and also can be used for pain-
predominant symptoms

REFERENCES

1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:

1393–407.
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders.
Gastroenterology 2006;130:1480–91.
 Irritable Bowel Syndrome 149

3. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharma-
col Ther 1997;11(1):3–15.
4. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the
United States. Gastroenterology 1991;100(4):998.
5. Sayuk GS, Wolf R, Chang L. Comparison of symptoms, healthcare utilization, and
treatment in diagnosed and undiagnosed individuals with diarrhea-predominant
irritable bowel syndrome. Am J Gastroenterol 2017;112(6):892.
6. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am
2011;40:1–10.
7. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syn-
drome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21.e4.
8. Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United
States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther
2005;21:1365–75.
9. Ikechi R, Fischer B, DeSipio J, et al. Irritable bowel syndrome: clinical manifesta-
tions, dietary influences, and management. Healthcare (Basel) 2017;5(2):21.
10. Walter SA, Ragnarsson G, Bodemar G. New criteria for irritable bowel syndrome
based on prospective symptom evaluation. Am J Gastroenterol 2005;100(11):
2598–9.
11. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defae-
cation in the irritable bowel syndrome (IBS). Patients’ description of diarrhea,
constipation and symptom variation during a prospective 6-week study. Eur J
Gastroenterol Hepatol 1998;10(5):415–21.
12. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the
irritable bowel. Br Med J 1978;2(6138):653.
13. Simren M, Olafur S, Palsson, et al. Update on Rome IV criteria for colorectal dis-
orders: implications for clinical practice. Curr Gastroenterol Rep 2017;19:15.
14. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position state-
ment on the management of irritable bowel syndrome. American College of
Gastroenterology Task Force on Irritable Bowel Syndrome. Am J Gastroenterol
2009;104(Suppl 1):S1.
15. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med
2012;367(17):1626–35.
16. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory,
psychologic, and autonomic functions in patients with irritable bowel syndrome.
Clin Gastroenterol Hepatol 2008;6:772–81.
17. Törnblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symp-
toms: what’s the link? Am J Gastroenterol 2012;107:754–60.
18. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the ir-
ritable colon syndrome. Gut 1973;14:125–32.
19. Lawal A, Kern M, Sidhu H, et al. Novel evidence for hypersensitivity of visceral
sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology
2006;130(1):26.
20. van der Veek PPJ, Steenvoorden J, Steens PJ, et al. Recto-colonic reflex is
impaired in patients with irritable bowel syndrome. Neurogastroenterol Motil
2007;19(8):653–9.
21. Simren M, Agerforz P, Björnsson S, et al. Nutrient-dependent enhancement of
rectal sensitivity in irritable bowel syndrome (IBS). Neurogastroenterol Motil
2007;19(1):20–9.
150 Alammar & Stein

22. Treem WR, Ahsan N, Kastoff G, et al. Fecal short-chain fatty acids in patients with
diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate
fermentation. J Pediatr Gastroenterol Nutr 1996;23:280–6.
23. Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic
transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Phys-
iol 2003;284:R1269–76.
24. Kamath PS, Hoepfner MT, Phillips SF. Short-chain fatty acids stimulate motility of
the canine ileum. Am J Physiol 1987;253:G427–33.
25. Shepherd SJ, Parker FC, Muir JG, et al. Dietary triggers of abdominal symptoms
in patients with irritable bowel syndrome: randomized, placebo-controlled evi-
dence. Clin Gastroenterol Hepatol 2008;6:765–71.
26. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal
symptoms in subjects without celiac disease: a double-blind randomized
placebo-controlled trial. Am J Gastroenterol 2011;106:508–14.
27. Camilleri M, Vazquez-Roque MI, Carlson P, et al. Randomized trial of gluten-free
diet in IBS-diarrhea: effect on small bowel and colonic morphology and barrier
function. Neurogastroenterol Motil 2012;24:23.
28. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free
diet in patients with irritable bowel syndrome-diarrhea: effects on bowel fre-
quency and intestinal function. Gastroenterology 2013;144(5):903–11.e3.
29. DiNicolantonio JJ, Lucan SC. Is fructose malabsorption a cause of irritable bowel
syndrome? Med Hypotheses 2015;85:295–7.
30. Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idio-
pathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients
with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther
2009;30:707–17.
31. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is asso-
ciated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol
2012;10:1009–15.
32. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist
in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome.
Neurogastroenterol Motil 2012;24:31–9.
33. Rajilic-Sotjanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis
of microbiota signatures in faecal samples from patients with irritable bowel syn-
drome. Gastroenterology 2011;141:1737–801.
34. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of
irritable bowel syndrome: a systematic review. Gut 2010;59:325–32.
35. Kim HJ, Camilleri M, McKinzie S, et al. A randomized, controlled trial of a probi-
otic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel
syndrome. Aliment Pharmacol Ther 2003;17:895–904.
36. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates
with symptom improvement in irritable bowel syndrome. a double-blind, random-
ized, placebo-controlled study. Am J Gastroenterol 2003;98(2):412.
37. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth
reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):
3503.
38. Chatterjee S, Park S, Low K, et al. The degree of breath methane production in
IBS correlates with the severity of constipation. Am J Gastroenterol 2007;
102(4):837.
39. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendo-
crine cells, T lymphocytes, and increased gut permeability following acute
 Irritable Bowel Syndrome 151

Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut

2000;47:804–11.
40. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology
2009;136:1979–88.
41. Lacy BE. The science, evidence, and practice of dietary interventions in irritable
bowel syndrome. Clin Gastroenterol Hepatol 2015;13:1899–906.
42. Shepherd SJ, Lomer MCE, Gibson PR. Short-chain carbohydrates and & func-
tional gastrointestinal disorders. Am J Gastroenterol 2013;108:707–17.
43. Hill P, Muir JG, Gibson PR. Controversies and recent developments of the low-
FODMAP diet. Gastroenterol Hepatol (N Y) 2017;13(1):36–45.
44. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am
J Gastroenterol 2013;108:718–27.
45. Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symp-
toms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology
2018;154(3):529.
46. Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients
with self-reported nonceliac gluten sensitivity after dietary reduction of ferment-
able, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:
320–8.
47. Zhu Y, Zheng X, Cong Y, et al. Bloating and distention in irritable bowel syndrome:
the role of gas production and visceral sensation after lactose ingestion in a pop-
ulation with lactase deficiency. Am J Gastroenterol 2013;108(9):1516.
48. Jones VA, Mclaughlan P, Shorthouse M, et al. Food intolerance: a major factor in
the pathogenesis of irritable bowel syndrome. Lancet 1982;2:1115–7.
49. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG anti-
bodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004;53:
1459–64.
50. Weinberg DS, Smalley W, Heidelbaugh JJ, et al. American Gastroenterological
Association institute guideline on the pharmacological management of irritable
bowel syndrome. Gastroenterology 2014;147:1146–8.
51. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irri-
table bowel syndrome. A systematic review and meta-analysis. J Clin Gastroen-
terol 2014;48(6):505–12.
52. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity—a re-
view. Chemotherapy 2005;51:67–72.
53. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated pri-
mary and secondary bile acids, and colonic transit in patients with irritable bowel
syndrome. Clin Gastroenterol Hepatol 2013;11:1270–5.e1.
54. Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids
and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment
Pharmacol Ther 2015;41:438–48.
55. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm. Accessed
June 13, 2018.
56. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients
with constipation-associated irritable bowel syndrome—results of two random-
ized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29(3):329.
57. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecana-
tide in patients with irritable bowel syndrome with constipation: results of two
phase 3 randomized clinical trials. Am J Gastroenterol 2018;113(5):735–45.
152 Alammar & Stein

58. Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the
management of irritable bowel syndrome and inflammatory bowel disease.
Aliment Pharmacol Ther 2015;41(11):1104–15.
59. Peters SL, Yao CK, Philpott H, et al. Randomised clinical trial: the efficacy of gut-
directed hypnotherapy is similar to that of the low FODMAP diet for the treatment
of irritable bowel syndrome. Aliment Pharmacol Ther 2016;44(5):447–59.
60. Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syn-
drome: a meta-analysis. World J Gastroenterol 2014;20:1871–7.
61. Zhao JM, Lu JH, Yin XJ, et al. Comparison of electroacupuncture and mild-warm
moxibustion on brain-gut function in patients with constipation-predominant irrita-
ble bowel syndrome: a randomized controlled trial. Chin J Integr Med 2018;24(5):
328–35.
62. Lackner J, Jaccard J, Keefer L, et al. Improvement in gastrointestinal symptoms
after cognitive behavior therapy for refractory irritable bowel syndrome. Gastro-
enterology 2018;155(1):47–57.